78 results about "Granulosa cell" patented technology

Methods and cell culture medium for the generation of human pluripotent embryonic stem cells are disclosed. Human embryonic stem cells are cultured with human granulosa feeder cells, muscle cells, Fallopian ductal epithelial cells, bone marrow stromal cells, and skin fibroblasts and the embryonic stem cells maintain their pluripotent phenotype. The human pluripotent embryonic stem cells can be cultured without feeder cells, and in the presence of supplemental growth factors. The human pluripotent embryonic stem cells can be alternatively cultured with conditioned medium obtained from a cell culture capable of maintaining human embryonic stem cells in a pluripotent state, wherein the cell culture is a human granulosa cell culture.

The present invention is related to a method for in vitro culture of mammalian ovarian follicles for bioassay purposes, comprising the following subsequent steps:-providing a suitable container for the in vitro culture,-selecting a follicle from an ovary of a mammal, said follicle comprising at least a theca or pre-theca cell, a granulosa cell and an oocyte,-an optional first culture step using an attachment prohibiting first medium free from oil,-a second culture step using an attachment promoting second medium free from oil arranged to, and-the retrieval of the matured follicle.

The invention relates to cell culture and particularly discloses an immature oocyte culture scheme which can promoting in-vitro maturation of immature oocytes. Specially, the scheme adopts follicular granulosa cells and a culture solution for culturing the follicular granulosa cells, wherein the culture solution for culturing the follicular granulosa cells contains CNP or its variants or analogues and an HDAC (histone deacetylase) inhibitor. The invention further provides an in-vitro maturation culture solution containing the CNP or its variants or analogues and the HDAC inhibitor and related compositions and application of a culture medium, the culture solution and the compositions in promotion of in-vitro maturation of immature oocytes.

A method for evaluating the quality of mammalian oocytes comprises determining the expression level of one or more of the genes ACPP, AQP11, CCDC126, CLU, CYP11 A1, CYP19A1, EGR3, FN1, FOSL2, GMNN, HRAS, HSD3B2, HS-D17B1, HSD11B2, HSDL1, IGF1, IGFBP4, IGFBP5, IRS1, KCNK3, KLF6, NEK6, SMAD7 or STC1 in a test sample derived from a cumulus cell or granulosa cell associated with the oocyte, and comparing the expression level of said at least one marker gene expression in the sample with the expression level in a control. Differential expression of the gene between the sample and the control is indicative of the quality of the oocyte.

The invention discloses a method for evaluating developmental potential of an oocyte by utilizing the relative expression of GRIM-19 in a granulosa cell. When the relative expression of the GRIM-19 in the granulosa cell of the oocyte is 0.16-0.35, the obtained oocyte is judged to be high in developmental potential; when the relative expression of the GRIM-19 is 0-0.12, the obtained oocyte is judged to be low in developmental potential; a beta-actin gene is selected for internal reference. The method disclosed by the invention is a more objective, accurate and quantizable oocyte quality evaluation method, is noninvasive without repeatedly taking out an incubator for observation, so that the adverse environmental stimulation is reduced. Due to being quantizable, the method disclosed by the invention has a specific numerical range, is easy to operate and solves the problem that due to artificial subjective factors, the judgment standards are not unified.

The present invention addresses the problem of providing a method for differentiating primordial germ cells into functionally mature GV stage oocytes by in vitro culture. The present invention pertains to a method for differentiating primordial germ cells into functional GV stage oocytes in vitro including (a) a step for forming secondary follicles by culturing primordial germ cells and feeder cells adjacent to the primordial germ cells under conditions that eliminate the effects of estrogen or factors having a similar function to estrogen, (b) a step for partially cleaving the bonds between the granulosa cell layer and the thecal cell layer among the oocyte, granulosa cell layer, and thecal cell layer that constitute the formed secondary follicles, and (c) a step for differentiating the oocytes into functional GV stage oocytes by culturing the oocytes and granulosa cell layer that constitute the secondary follicles and the thecal cell layer in medium including a polymer compound.

The invention provides a method for detecting chromosome abnormality of embryos by the aid of blastocyst cultivation solution without zona pellucida. The method which is particularly an in-vitro non-therapeutic method for detecting the chromosome abnormality of the embryos by the aid of the blastocyst cultivation solution includes steps of (a), providing the cultivation solution from blastocyst cultivation systems; (b), carrying out gene detection on the cultivation solution so as to authenticate whether chromosomes of the embryos are abnormal or not. The zona pellucida of the embryos in the blastocyst cultivation systems is removed before the embryos are cultivated, the embryos are cultivated in the blastocyst systems for 3-6 days, and preferably, the cultivation solution is separated from the cultivation systems after 4 days. The method has the advantages that contamination and interference risks due to redundant sperms and parent-source granular cells in IVF (in-vitro fertilization) and ICSI (intracytoplasmic sperm injection) technical procedures can be eliminated, and whether the chromosomes of the embryos are abnormal or not can be accurately authenticated.

Nucleic acid compositions encoding a pro-apoptotic protein, Bok (Bcl-2-related ovarian killer) are identified. Bok has conserved Bcl-2 homology domains 1, 2 and 3 and a C-terminal transmembrane region present in other Bcl-2 related proteins, but lacks the BH4 domain found only in anti-apoptotic Bcl-2 proteins. Over-expression of Bok induces apoptosis. Cell killing induced by Bok is suppressed by co-expression with selective anti-apoptotic Bcl-2 proteins. Bok is highly expressed in the ovary, testis and uterus, particularly in granulosa cells, the cell type that undergoes apoptosis during follicle atresia. Identification of Bok as a new pro-apoptotic protein with wide tissue distribution and hetero-dimerization properties facilitates elucidation of apoptosis mechanisms in reproductive and other tissues, and provides a means for manipulating apoptosis.

The invention discloses a separation, primary culture and subculture method for granulosa cells in follicles in a pig ovary GV period. The method comprises the following steps: collecting a cyst-free healthy pig ovary, and cleaning the ovary; separating granular cells; carrying out primary culture on the granular cells for 48 hours; changing liquid in a culture bottle for primary culture; after changing the liquid, continuously culturing the cells for 36 hours, and cleaning, digesting and terminating the cultured cells; and finally, sub-packaging and subculturing the cells for 48 hours. The invention provides a pollution-free ovary collection method, optimizes a granulosa cell acquisition and culture method, and further provides a primary granulosa cell subculture method. Granular cells obtained by the method are almost free of pollution, high in cell uniformity, high in consistency in the growth and development period, high in cell survival rate, high in success rate of making oxidative stress models and the like, and high in result consistency, practicability, stability and feasibility. In addition, the number of obtained cells is large, many subsequent experiments can be carried out, the number of times of going to a slaughter house is reduced, and the efficiency is high.

The invention relates to a recombinant human granulosa cell enzyme solution and a preparation method of same and belongs to the technical field of artificial assisted reproduction. The recombinant human granulose cell enzyme solution is prepared by dissolving recombinant human granulosa cell enzyme dry powder, which is obtained by processing ovum, in a salt solution containing antibiotics and an indicator. In the invention, by means of a physiological work solution, which is prepared by means of non-animal-sourced recombinant bio-engineering high-tech hyaluronidase (a.k.a. recombinant human granulosa cell enzyme) dry powder, is 80 units (I.U.) and has functional available concentration, not only are granule cells surrounding the ovum effectively digested, which is beneficial to introcytoplasmic sperm injection (ICSI) technology of the ovum, but also possibility of animal-sourced pathogen and toxin are effectively excluded, thereby greatly improving safety of assisted reproduction.

The present invention provides compositions and methods for regulating fertility in mammals. In general, the invention relates to a novel protein produced by oocytes named JY-1, and nucleic acids encoding the JY-1 protein, for controlling folliculogenesis and early embryonic development, particularly in monoovulatory species. In particular, the present invention provides nucleic acid and amino acid sequences encoding JY-1, vectors for the expression of JY-1, host cells expressing JY-1, RNAi probes for reducing levels of JY-1 message, and antibodies to JY-1. Specifically, developing and mature oocytes express JY-1 in vivo, while granulosa cells treated in vitro with recombinant JY-1 (rJY-1) protein reduced cell proliferation while increasing progesterone synthesis and estradiol production. Further, reducing JY-1 protein in developing embryos in vitro using inhibitory siRNA constructs corresponded with arrested blastocyte maturation.

The invention relates to a method for culturing an in-vitro fertilized embryo of a mammal. The method comprises the following steps of collection and in-vitro maturation of an oocyte; in-vitro fertilization; in-vitro culture and preservation of the embryo. During in-vitro fertilization, mature COCs are cultured in a fertilization culture solution. During in-vitro culture of the embryo, granulosa cells around the embryo are removed by an egg stripping needle, the embryo is cultured in an embryo culture liquid, and the available embryo after culture is completed is cryopreserved in a freezing liquid with liquid nitrogen. The method has excellent technical effects described in the description.

The invention discloses an application of FGFR1 genes to granulosa cells of sows, and belongs to the technical field of cell engineering and genetic engineering. The FGFR1 genes can be used for detecting the relative expression quantity of FGFR1 mRNA in ovarian tissues of sows of 180 days old (the ovarian is immature ) and sows of 200 days old (the ovarian is mature), and granulosa cells of different size, and the proliferation and apoptosis situation of the granulosa cells after overexpression/interference FGFR1, so as to accumulate materials for the molecule mechanism in the development process of the granulosa cells of the sows. Besides, the results show that the FGFR1 genes participate in promoting proliferation of the granulosa cells, and restraining the apoptosis of the granulosa cells, and further, the results indicate that the FGFR1 genes can participate in development and mature of the granulosa cells of the sows.

The invention discloses a method for breeding transgenic buffalos by using somatic cell nuclear transfer technology, which comprises: obtaining buffalo fetal fibroblasts (BFF) by separation from buffalo fetuses and culture, implanting a transgenic vector (pCE-EGFP-IRES-neo), which carries a neomycin resistant gene and an enhanced green fluorescent protein (EGFP) gene, into the BFF by an electroporation process, and selecting BFF into which the EGFP gene is transferred by using G418; transplanting the BFF into which the EGFP gene is transferred into denucleated oocytes of the buffalo to construct cloned embryos, treating the cloned embryos for 5 minutes with ionomycin at a concentration of 5 mu mol/L, culturing cloned embryos in 6-dimethyl-aminopurine at a concentration of 2mmol/L for 3 hours, performing chemical activation treatment, co-culturing the cloned embryos in granulose cell monolayer liquid drops for 6 to 7 days, and obtaining the transgenic cloned blastaea; selecting transgenic cloned blastaea in which the EGFP is expressed under a reversed fluorescence microscope, and transplanting the transgenic cloned blastaea into receptor buffalos; and obtaining the transgenic buffalos after full-term pregnancy. After the irradiation by an ultraviolet lamp, the EGFP marker genes are obviously expressed in the heads and limbs of the transgenic buffalo calves, and this proves the method disclosed by the invention can successfully breed transgenic cloned buffalos.

The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating premature ovarian failure. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8-20 parts of radix rehmanniae preparata, 6-10 parts of fructus corni, 10-30 parts of Chinese yam, 10-15 parts of fructus lycii, 6-10 parts of tortoise-plastron glue, 6-10 parts of deer-horn glue, 10-25 parts of semen cuscutae, 6-10 parts of radix cyathulae, 10-15 parts of fructus psoraleae, 10-15 parts of herba taxilli, 10-15 parts of radix dipsaci, 6-10 parts of ginseng, 10-30 parts of radix astragali, 6-10 parts of rhizoma atractylodis macrocephalae, 10-15 parts of radix angelicae sinensis, 10-15 parts of radix paeoniae alba, 6-10 parts of pericarpium citri reticulatae and 6-10 parts of radix glycyrrhizae preparata. The traditional Chinese medicine composition for treating premature ovarian failure can effectively inhibit apoptosis of granulosa cells, promote follicular maturation and improve ovarian reserve capacity, and is high in safety.

The invention discloses an application of chi-miR-450-5p as an miRNA marker for maturation of goat follicles. The chi-miR-450-5p provided by the invention can reflect the maturation of goat follicles,and has reliability, universality and repeatability as a follicle development marker. The invention also discloses a test kit for detecting the development condition of the goat follicles. Accordingto the invention, through separation of follicle granulosa cells, the expression mode of the chi-miR-450-5p in dominant follicles and small follicle granulosa cells is verified, and a basis is provided for perfecting a goat follicle growth and development, ovulation gene regulation and non-coding regulation network.

The invention belongs to the technical field of genetic engineering and provides laying duck circRNA circ_13034 and a detection reagent, a method and an application thereof. A cDNA sequence corresponding to the laying duck circRNA circ_13034 provided by the invention is shown in SEQ ID NO: 1. The invention further provides a fluorescent quantitative PCR detection primer pair and a detection kit ofthe laying duck circRNA. The detection primer pair has nucleotide sequences shown in SEQ ID NO: 2 and SEQ ID NO: 3. The invention further provides an overexpression vector of the laying duck circRNAcirc_13034 and a construction method thereof. The invention further provides application of the laying duck circRNA and the overexpression vector in differentiation of laying duck follicle developmentconditions and detection of cell proliferation and differentiation conditions of laying duck follicle granulosa cells as molecular markers. The application has an important significance in researching inheritance of proliferation character of laying duck and improving reproductivity of the laying duck.